Recurrence / refractory CD19 + leukemia, lymphoma
Conditions
Interventions
Case series:Pretreated with cyclophosphamide
Infusion with 1-5×10^6 CAR-T(+) cell/kg by I.V.
Sponsors
Affiliated Hospital of Nanjing University of Chinese Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Aged between 18-75 years old male or female; 2) Diagnosed with CD19 + B cell malignancy and no other effective treatment options (such as autologous or allogeneic stem cell transfusion); 3) the use of the current treatment of poor prognosis (= 12 weeks to <2 years of survival).;Inclusion criteria: 1) Aged between 18-75 years old male or female; 2) Diagnosed with CD19 + B cell malignancy and no other effective treatment options (such as autologous or allogeneic stem cell transfusion); 3) the use of the current treatment of poor prognosis (= 12 weeks to <2 years of survival).;Inclusion criteria: 1) Aged between 18-75 years old male or female; 2) Diagnosed with CD19 + B cell malignancy and no other effective treatment options (such as autologous or allogeneic stem cell transfusion); 3) the use of the current treatment of poor prognosis (= 12 weeks to <2 years of survival).;Inclusion criteria: 1) Aged between 18-75 years old male or female; 2) Diagnosed with CD19 + B cell malignancy and no other effective treatment options (such as autologous or allogeneic stem cell transfusion); 3) the use of the current treatment of poor prognosis (= 12 weeks to <2 years of survival).;Inclusion criteria: 1) Aged between 18-75 years old male or female; 2) Diagnosed with CD19 + B cell malignancy and no other effective treatment options (such as autologous or allogeneic stem cell transfusion); 3) the use of the current treatment of poor prognosis (= 12 weeks to <2 years of survival).
Exclusion criteria
Exclusion criteria: 1) Pregnant or lactating women; 2) uncontrolled positive infection, including but not limited to hepatitis B, hepatitis C, syphilis, AIDS positive and active; 3) Use systemic steroids; 4) Previously received any other gene therapy.;Exclusion criteria: 1) Pregnant or lactating women; 2) uncontrolled positive infection, including but not limited to hepatitis B, hepatitis C, syphilis, AIDS positive and active; 3) Use systemic steroids; 4) Previously received any other gene therapy.;Exclusion criteria: 1) Pregnant or lactating women; 2) uncontrolled positive infection, including but not limited to hepatitis B, hepatitis C, syphilis, AIDS positive and active; 3) Use systemic steroids; 4) Previously received any other gene therapy.;Exclusion criteria: 1) Pregnant or lactating women; 2) uncontrolled positive infection, including but not limited to hepatitis B, hepatitis C, syphilis, AIDS positive and active; 3) Use systemic steroids; 4) Previously received any other gene therapy.;Exclusion criteria: 1) Pregnant or lactating women; 2) uncontrolled positive infection, including but not limited to hepatitis B, hepatitis C, syphilis, AIDS positive and active; 3) Use systemic steroids; 4) Previously received any other gene therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cytokine release;CAR-T proliferation;Bone marrow examination; | — |
Countries
China
Contacts
Public ContactXuejun Zhu;Xuejun Zhu;Xuejun Zhu;Xuejun Zhu;Xuejun Zhu ;;;;
Affiliated Hospital of Nanjing University of Chinese Medicine;Affiliated Hospital of Nanjing University of Chinese Medicine;Affiliated Hospital of Nanjing University of Chinese Medicine;Affiliated Hospital of Nanjing University of Chinese Medicine;Affiliated Hospital of Nanjing University of Chinese Medicine
Outcome results
None listed